• Able to understand and provide informed consent
• Age between 18 and 60 years inclusive
• Male or Female

Healthy Normal Control Group:

• No history of asthma, COPD, rhinitis, or other significant respiratory diseases
• Non-smoker or ex-smoker with less than 10 pack years, quit at least 5 years ago
• No history of diabetes or cardiovascular disease
• Negative ImmunoCAP test or documented negative skin test or specific IgE for relevant allergens within past 12 months

Allergic Rhinitis Group:

• History of physician-diagnosed rhinitis with seasonal or perennial nasal congestion, sneezing, or conjunctival infection
• No history of asthma, COPD, or other significant respiratory diseases
• Non-smoker or ex-smoker with less than 10 pack years, quit at least 5 years ago
• No history of diabetes or cardiovascular disease
• Positive ImmunoCAP test to cat dander or documented positive skin test or specific IgE
• Regular exposure to cat dander via home environment
• No evidence of airway obstruction on spirometry

Allergic Asthma Group:

• History of physician-diagnosed mild to moderate asthma
• No history of COPD or other significant respiratory diseases besides asthma
• Non-smoker or ex-smoker with less than 10 pack years, quit at least 5 years ago
• No history of diabetes or cardiovascular disease
• Airway obstruction reversible with albuterol or requiring inhaled corticosteroids for asthma control within past 12 months
• Positive ImmunoCAP test to cat dander or documented positive skin test or specific IgE
• Regular exposure to cat dander
• Normal complete blood count without clinically important abnormalities

Healthy Group:

• Unable or unwilling to comply with study protocol
• Currently taking inhaled corticosteroids, leukotriene modifiers, or antihistamines for respiratory disease
• Neutralizing antibody to RV16 ≥ 1:8
• Pregnant, breastfeeding, or planning pregnancy during study
• Household contacts who are pregnant, have chronic respiratory disease, are children under 2 years, adults over 60 years, or immunosuppressed
• Providing healthcare services or working with elderly or children

Allergic Rhinitis Group:

• Unable or unwilling to comply with study protocol
• Currently using inhaled steroids or oral montelukast
• Neutralizing antibody to RV16 ≥ 1:8
• Pregnant, breastfeeding, or planning pregnancy during study
• Household contacts as above
• Providing healthcare services or working with elderly or children
• Immunosuppressive treatment within past 12 months
• BMI over 35
• Symptoms of viral upper respiratory infection within past 21 days
• Abnormal complete blood count
• Family or personal history of liver disease or bleeding disorders
• No systemic corticosteroids within 3 months before screening
• Use of antiplatelet agents other than aspirin
• Positive COVID-19 test within past 8 weeks

Allergic Asthma Group:

• Unable or unwilling to comply with study protocol
• Taking respiratory medications other than ICS, montelukast, rescue albuterol, or LABAs
• Neutralizing antibody to RV16 ≥ 1:8
• FEV1:FVC ratio less than 0.6 or FEV1 less than 60% predicted
• Recent asthma exacerbation requiring systemic corticosteroids within 30 days
• ICS dose greater than fluticasone 500 mcg/day or equivalent
• Pregnant, breastfeeding, or planning pregnancy during study
• Household contacts as above
• Providing healthcare services or working with elderly or children
• Immunosuppressive treatment within past 12 months
• BMI over 35
• Symptoms of viral upper respiratory infection within past 21 days
• Family or personal history of liver disease or bleeding disorders
• No systemic corticosteroids within 3 months before screening
• ACT score over 19 at enrollment
• Use of antiplatelet agents other than aspirin
• Positive COVID-19 test within past 8 weeks